Alert detail
FDA Approval: WIDAPLIK (TELMISARTAN, AMLODIPINE AND INDAPAMIDE) — Type 4 - New Combination
Policy ID: FDA-NDA219423Specialty: CardiologyAdded: 6/5/2026Effective: 2025-06-05federal register
What changed
New oral combination drug WIDAPLIK approved for billing.
Who’s affected: Cardiology billing teams · Effective: 2025-06-05
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.
Not ready to subscribe?
Get the free weekly reimbursement brief for Cardiology— the week’s changes and deadlines, delivered to your inbox. No account required.